



Trust Headquarters
East Surrey Hospital
Canada Avenue
Redhill
RH1 5RH

Tel: 01737 768511
www.sash.nhs.uk

Our ref: 4773

12 June 2018

Freedom of information request

I am writing in response to your request for information which has been handled under the Freedom of Information Act 2000 (FOIA).

In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide.

Please provide the number of patients by treatment for the following disease modifying drugs.

Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Copaxone (glatiramer acetate)
Glatiramer acetate generic [eg Brabio]
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Lemtrada (alemtuzumab)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Ampyra (Fampyra)
Peginterferon beta-1a (Plegridy)
Daclizumab (Zinbryta)
Cladribine (Mavenclad)

[Please see table below](#)

MS Drugs October 2017 to March 2018	Number of patients
Aubagio (teriflunomide)	
Avonex (interferon beta-1a)	11
Betaferon (interferon beta-1b)	3
Copaxone (glatiramer acetate)	
Glatiramer acetate generic [eg Brabio]	33
Extavia (beta interferon-1b)	
Gilenya (fingolimod)	
Lemtrada (alemtuzumab)	
Rebif (beta interferon-1a)	10
Tecfidera (dimethyl fumarate)	49
Tysabri (natalizumab)	
Ampyra (Fampyra)	
Peginterferon beta-1a (Plegridy)	
Daclizumab (Zinbryta)	
Cladribine (Mavenclad)	